Dynavax Technologies Corporation (LON:0IDA)
9.44
-0.16 (-1.72%)
At close: Sep 12, 2025
Dynavax Technologies Revenue
Dynavax Technologies had revenue of $95.44M USD in the quarter ending June 30, 2025, with 29.33% growth. This brings the company's revenue in the last twelve months to $316.27M, up 26.66% year-over-year. In the year 2024, Dynavax Technologies had annual revenue of $277.25M with 19.36% growth.
Revenue (ttm)
$316.27M
Revenue Growth
+26.66%
P/S Ratio
3.61
Revenue / Employee
$780.91K
Employees
405
Market Cap
833.50M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 277.25M | 44.96M | 19.36% |
Dec 31, 2023 | 232.28M | -490.40M | -67.86% |
Dec 31, 2022 | 722.68M | 283.24M | 64.45% |
Dec 31, 2021 | 439.44M | 399.19M | 991.75% |
Dec 31, 2020 | 40.25M | 5.03M | 14.29% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Dynavax Technologies News
- 21 days ago - Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference - PRNewsWire
- 27 days ago - Dynavax Says Investigational Shingles Vaccine At Par With GSK's Vaccine In Early-Stage Study - Benzinga
- 27 days ago - Dynavax says shingles shot performed on par with GSK’s Shingrix in Phase 1/2 trial - Seeking Alpha
- 27 days ago - Dynavax's shingles vaccine shows similar immune response to GSK's shot in study - Reuters
- 27 days ago - Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile - PRNewsWire
- 5 weeks ago - Dynavax Technologies: A Dip To Accumulate - Seeking Alpha
- 5 weeks ago - Dynavax Technologies Corporation 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 5 weeks ago - Dynavax raises 2025 HEPLISAV-B revenue guidance to $315M-$325M and targets 60% U.S. market share by 2030 as retail momentum grows - Seeking Alpha